Health Care [ 1/12 ] | Health Care Equipment & Supplies [ 17/74 ]
NASDAQ | Common Stock
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.
The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle.
It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion.
In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix.
The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products.
Its products also include Exogen, an ultrasound bone stimulation system.
The company sells its products to healthcare institutions, physicians, patients, distributors and dealers.
Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| May 6, 26 | 0.15 Increased by +475.94% | 0.07 Increased by +120.59% |
| Mar 17, 26 | 0.24 Increased by +60.00% | 0.20 Increased by +17.53% |
| Nov 4, 25 | 0.15 Increased by +150.00% | 0.11 Increased by +36.36% |
| Aug 6, 25 | 0.21 Increased by +10.53% | 0.21 |
| May 5, 25 | -0.04 Decreased by -157.00% | 0.02 Decreased by -275.00% |
| Mar 10, 25 | 0.15 Increased by +114.29% | 0.09 Increased by +76.47% |
| Nov 5, 24 | 0.06 Increased by +20.00% | 0.03 Increased by +100.00% |
| Aug 6, 24 | 0.19 Increased by +35.71% | 0.07 Increased by +171.43% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Mar 31, 26 | 132.09 M Increased by +6.63% | 3.11 M Increased by +218.05% | Increased by +2.36% Increased by +210.71% |
| Dec 31, 25 | 157.90 M Increased by +2.77% | 14.76 M Increased by +9.56 K% | Increased by +9.34% Increased by +9.30 K% |
| Sep 30, 25 | 138.65 M Decreased by -0.23% | 3.15 M Increased by +165.40% | Increased by +2.28% Increased by +165.55% |
| Jun 30, 25 | 147.66 M Decreased by -2.35% | 7.46 M Increased by +129.04% | Increased by +5.05% Increased by +129.74% |
| Mar 31, 25 | 123.88 M Decreased by -4.31% | -2.64 M Increased by +46.07% | Decreased by -2.13% Increased by +43.64% |
| Dec 31, 24 | 153.64 M Increased by +13.45% | -156.00 K Increased by +97.44% | Decreased by -0.10% Increased by +97.74% |
| Sep 30, 24 | 138.96 M Increased by +15.04% | -4.82 M Increased by +33.94% | Decreased by -3.47% Increased by +42.58% |
| Jun 30, 24 | 151.22 M Increased by +10.32% | -25.68 M Decreased by -597.69% | Decreased by -16.98% Decreased by -532.41% |